FDA Cites Auriga Research Pvt. Ltd. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
At a glance: The FDA's Center for Drug Evaluation and Research issued a warning letter to Auriga Research Pvt. Ltd. (FEI 3019975128), a contract testing laboratory in Bengaluru, India, on August 12, 2026 (Reference #320-26-113), following an inspection February 4-6, 2026, citing significant Current Good Manufacturing Practice violations for finished pharmaceuticals. The primary violation involved failure to ensure laboratory records included complete data from all required tests, including microbial testing with blank spaces on raw data sheets and incomplete plate count documentation, which the FDA stated compromised data integrity and the quality unit's ability to ensure compliance with applicable standards. The FDA rejected the firm's February 27, 2026 response as inadequate for lacking assessment of the paper-based documentation system vulnerabilities and retrospective review of additional incomplete or non-contemporaneous documentation instances, and required submission of a comprehensive independent assessment of laboratory practices and detailed remediation plan.
Argus analysis
# FDA Warning Letter Analysis: Auriga Research Pvt. Ltd.
**Company and Findings**
Auriga Research Pvt. Ltd., a contract testing laboratory based in Bengaluru, India (FEI 3019975128), received a warning letter from the FDA's Center for Drug Evaluation and Research on August 12, 2026, following an inspection conducted February 4–6, 2026. The FDA identified significant Current Good Manufacturing Practice (CGMP) violations in the facility's testing of finished pharmaceutical products intended for the US market. The agency determined that drug products tested by Auriga are considered adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act due to failures in methods, facilities, and controls.
**Regulatory Citations and Meaning**
The warning letter cites two primary violations under 21 CFR parts 210 and 211. First, 21 CFR 211.194(a) addresses laboratory record completeness—Auriga failed to maintain contemporaneous, original documentation of microbial testing data, with raw data sheets containing blank entries where test results should have appeared. Second, 21 CFR 211.22(d) requires adequate written quality unit responsibilities and procedures; Auriga's quality unit approved investigations that lacked scientific justification, including cases where the laboratory repeated testing until obtaining passing results without addressing root causes—a practice the FDA identifies as "testing into compliance," which is objectionable under CGMP standards.
**Timeline and Industry Monitoring**
Auriga submitted a response on February 27, 2026, which the FDA deemed inadequate on multiple counts. The company must now provide comprehensive independent assessments, detailed corrective action and preventive action (CAPA) plans, and documentation system remediation overseen by qualified consultants. Peer compliance officers should monitor whether Auriga engages external expertise, implements digital time-stamped documentation systems, and demonstrates sustained procedural changes. Regulatory actions may follow if remediation efforts remain insufficient.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Auriga Research Pvt. Ltd. MARCS-CMS 730694 — August 12, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE Reference #: 320-26-113 Product: Drugs Recipient: Recipient Name Dr. Saurabh Arora Recipient Title Managing Director and CEO Auriga Research Pvt. Ltd. 3/17 Kirti Nagar, Industrial Area New Delhi 110015 India (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 12, 2026 WARNING LETTER Reference number: 320-26-113 To Dr. Saurabh Arora: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your contract testing laboratory. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice. FDA Inspection Violations were observed and documented during an inspection of your contract testing laboratory, Auriga Research Pvt. Ltd., FEI 3019975128, at No. 136, 6th Cross, 2nd Stage, Yeshwanthpur Industrial Suburb, Bengaluru, India, from February 4 to 6, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, drug products you tested are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your February 27, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility. 1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)). Your firm is a contract testing laboratory that conducts testing of various application and nonapplication drug products for the US market. Your laboratory records lacked complete and original data demonstrating that you performed the required testing. You did not a…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Auriga Research Pvt. Ltd. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Auriga Research Pvt. Ltd. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-auriga-research-pvt-ltd-2026-08-12-cgmp
"FDA Cites Auriga Research Pvt. Ltd. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-auriga-research-pvt-ltd-2026-08-12-cgmp.
Argus HQ Research. "FDA Cites Auriga Research Pvt. Ltd. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-auriga-research-pvt-ltd-2026-08-12-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_auriga_research_pvt_ltd_2026_08_12_cgmp_2026,
title = {FDA Cites Auriga Research Pvt. Ltd. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-auriga-research-pvt-ltd-2026-08-12-cgmp},
note = {Accessed: August 19, 2026}
}